Endometrial Hiperplazi ve Kanser Tanılı Hastalarda Periferik Kan İnflamasyon İndekslerinin Rolü

Year 2024, Volume: 6 Issue: 4, 147 - 152, 06.11.2024

Muradiye Yıldırım , Hasan Altınsoy , Eylem Ünlübilgin , Yaprak Ustun

https://doi.org/10.46969/EZH.1572727

Abstract

Amaç: Endometrium kanseri (EK) , özellikle gelişmiş ülkelerde artan sıklığıyla önemli bir sorundur. Henüz genel kabul görmüş bir tarama programı yoktur. En önemli risk faktörü olan endometrial hiperplazinin (EH) yönetimi, invaziv bir süreç olması nedeniyle karmaşıktır.
Gereç ve Yöntem: Toplam 72 hasta ile retrospektif bir çalışma yürütüldü. Anormal uterin kanaması ve transvajinal sonografide artmış endometrial kalınlığı olan 35-65 yaş arasındaki hastalar patoloji sonuçlarıyla değerlendirildi. Hastaların sosyodemografik özellikleri ve hastane yatışındaki laboratuvar değerleri hastane kayıtlarından elde edildi. Beyaz kan hücreleri (WBC), nötrofiller, lenfositler, monositler, eozinofiller, bazofiller ve trombosit sayıları (x10⁹/L); plateletcrit (%), hemoglobin (Hb) (g/dL) ve hematokrit (Htc) (%) değerleri kaydedildi. Nötrofil lenfosit oranı (NLO), monosit lenfosit oranı (MLO) ve trombosit lenfosit oranı (TLO) elde edildi. Sistemik immün-inflamasyon indeksi (SII), sistemik inflamasyon yanıt indeksi (SIRI) ve pan-immün-inflamasyon değeri (PIV) elde edildi. Verilerin dağılımı SPSS ile programı ile analiz edildi. Parametrik veriler bağımsız örneklem t-testi ile incelendi. 0,05’ten küçük p değeri anlamlı kabul edildi.
Bulgular: EH tanısı almış 37 hasta ve endometrial malignite tanısı almış 35 hasta çalışmaya dahil edildi. EH grubunun yaş ortalaması 45,5 yıl iken malign grubun yaş ortalaması 50,5 yıl idi (p=0,027). Hastaların sosyodemografik özellikleri benzer bulundu. Tam kan sayımı parametrelerinde iki grup arasında istatistiksel olarak anlamlı fark yoktu. Sistemik inflamatuar indeksler gruplar arasında karşılaştırıldı. EH ve EK gruplarında ortalama NLR değerleri sırasıyla 2,33 ve 2,52 idi, p=0,448. MLO ortalama değerleri sırasıyla 0,20 ve 0,21 idi, p=0,498. TLO ortalama değerleri sırasıyla 0,16 ve 0,15 idi, p=0,811. SII ortalama değerleri sırasıyla 720,1 ve 812,4 (x10⁹/L) idi, p=0,456. SIRI’nin ortalama değerleri sırasıyla 943,1 ve 1095,6 (x10⁹/L) idi, p = 0,257. PIV’nin ortalama değerleri sırasıyla 312753,6 ve 352975,1 (x10⁹/L) idi, p = 0,514.
Sonuç: Periferik kan inflamasyon indeksleri son zamanlarda kanser tanısı ve takibinde kullanılmaktadır. EH ve EK hasta grupları arasında araştırılan parametreler arasında istatistiksel olarak herhangi bir anlamlı fark bulamadık. EH’li kadınlarda ek risk faktörlerinin varlığında yakın takip gereklidir.

Keywords

endometrial kanser, endometrial hiperplazi, sistemik immün-inflamasyon indeksi, sistemik inflamasyon yanıt indeksi, pan-immün-inflamasyon değeri

The Role of Peripheral Blood Inflammation Indices in Patients with a Diagnosis of Endometrial Hyperplasia and Cancer

Abstract

Purpose: Endometrial cancer (EC) is an important problem with its increasing incidence, especially in developed countries. There is no generally accepted screening program yet. The management of endometrial hyperplasia (EH), which is the most important risk factor, is complex because it is an invasive process.
Methods: A retrospective study was conducted with a total of 72 patients. Patients between the ages of 35-65 with abnormal uterine bleeding, and increased endometrial thickness on transvaginal sonography were evaluated with pathology results. Sociodemographic characteristics of the patients and laboratory values at hospital admission were obtained from hospital records. White blood cells (WBC), neutrophils, lymphocytes, monocytes, eosinophils, basophils, and thrombocyte counts (x10⁹/L); plateletcrit (%), hemoglobin (Hb) (g/dL), and hematocrit (Htc) (%) values were recorded. Neutrophil lymphocyte ratio (NLR), monocyte lymphocyte ratio (MLR), and thrombocyte lymphocyte ratio (TLR) were obtained. Systemic immune-inflammation index (SII), systemic inflammation response index (SIRI) and pan-immune-inflammation value (PIV) were obtained.
Results: Thirty-seven patients diagnosed with EH and 35 patients diagnosed with endometrial malignancy were included. The mean age of the EH was 45.5 years and the mean age of the malignant group was 50.5 years (p=0.027). The sociodemographic characteristics of the patients were found to be similar. There was no significant difference in complete blood count parameters between two groups. Mean values of NLR were 2.33 and 2.52 in EH and EC groups, respectively, p = 0.448. Mean values of MLR were 0.20 and 0.21, respectively, p = 0.498. Mean values of TLR were 0.16 and 0.15, respectively, p = 0.811. Mean values of SII were 720.1 and 812.4 (x10⁹/L), respectively, p = 0.456. Mean values of SIRI were 943.1 and 1095.6 (x10⁹/L), respectively, p = 0.257. Mean values of PIV were 312753.6 and 352975.1 (x10⁹/L), respectively, p = 0.514.
Conclusion: Peripheral blood inflammation indices have recently been used in cancer diagnosis and follow-up. We did not find any statistically significant differences in the investigated parametrers between the EH and EC patient groups. Close follow-up is necessary in the presence of additional risk factors in women with EH.

Keywords

endometrial cancer, endometrial hyperplasia, systemic immune-inflammation index, systemic inflammation response index, pan-immune-inflammation value

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492
• Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global Cancer in Women: Burden and Trends. Cancer Epidemiol Biomarkers Prev. 2017;26(4):444-57. https://doi.org/10.1158/1055-9965.EPI-16-0858
• Sanderson PA, Critchley HO, Williams AR, Arends MJ, Saunders PT. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017;23(2):232-54. https://doi.org/10.1093/humupd/dmw042
• Johnatty SE, Tan YY, Buchanan DD, et al. Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. Gynecol Oncol. 2017;147(2):381-7. https://doi.org/10.1016/j.ygyno.2017.08.011
• Doherty MT, Sanni OB, Coleman HG, et al. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis. PLoS One. 2020;15(4):e0232231. https://doi.org/10.1371/journal.pone.0232231
• Lacey JV, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas. 2009;63(1):39-44. https://doi.org/10.1016/j.maturitas.2009.02.005
• Petersdorf K, Groettrup-Wolfers E, Overton PM, Seitz C, Schulze-Rath R. Endometrial hyperplasia in pre-menopausal women: A systematic review of incidence, prevalence, and risk factors. Eur J Obstet Gynecol Reprod Biol. 2022;271:158-71. https://doi.org/10.1016/j.ejogrb.2022.02.015
• Zhao J, Hu Y, Zhao Y, Chen D, Fang T, Ding M. Risk factors of endometrial cancer in patients with endometrial hyperplasia: implication for clinical treatments. BMC Womens Health. 2021;21(1):312. https://doi.org/10.1186/s12905-021-01452-9
• Tavares-Murta BM, Mendonça MA, Duarte NL, et al. Systemic leukocyte alterations are associated with invasive uterine cervical cancer. Int J Gynecol Cancer. 2010;20(7):1154-9. https://doi.org/10.1111/igc.0b013e3181ef8deb
• Shen X, Xiang M, Tang J, et al. Evaluation of peripheral blood inflammation indexes as prognostic markers for colorectal cancer metastasis. Sci Rep. 2024;14(1):20489. https://doi.org/10.1038/s41598-024-68150-y
• Zhang Y, Wu J, Chen W, Liang X. Pretreatment System Inflammation Response Index (SIRI) is a Valuable Marker for Evaluating the Efficacy of Neoadjuvant Therapy in Breast Cancer Patients. Int J Gen Med. 2024;17:4359-68. https://doi.org/10.2147/IJGM.S478000
• Wang QY, Zhong WT, Xiao Y, et al. Pan-immune-inflammation value as a prognostic biomarker for colon cancer and its variation by primary tumor location. World J Gastroenterol. 2024;30(33):3823-36. https://doi.org/10.3748/wjg.v30.i33.3823
• Lin H, Zhong W, Zhong L, Que C, Lin X. The inflammatory markers combined with CA125 may predict postoperative survival in endometrial cancer. J Obstet Gynaecol. 2024;44(1):2373937. https://doi.org/10.1080/01443615.2024.2373937
• Bhat AA, Nisar S, Singh M, et al. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy. Cancer Commun (Lond). 2022;42(8):689-715. https://doi.org/10.1002/cac2.12295
• Raffone A, Travaglino A, Gabrielli O, et al. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer. Arch Gynecol Obstet. 2021;303(6):1393-400. https://doi.org/10.1007/s00404-021-06028-4
• Suh DH, Kim HS, Chung HH, et al. Pre-operative systemic inflammatory response markers in predicting lymph node metastasis in endometrioid endometrial adenocarcinoma. Eur J Obstet Gynecol Reprod Biol. 2012;162(2):206-10. https://doi.org/10.1016/j.ejogrb.2012.02.028
• Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009;58(1):15-23. https://doi.org/10.1007/s00262-008-0516-3
• Ji P, He J. Prognostic value of pretreatment systemic immune-inflammation index in patients with endometrial cancer: a meta-analysis. Biomark Med. 2024;18(7):345-56. https://doi.org/10.2217/bmm-2023-0629
• Njoku K, Ramchander NC, Wan YL, Barr CE, Crosbie EJ. Pre-treatment inflammatory parameters predict survival from endometrial cancer: A prospective database analysis. Gynecol Oncol. 2022;164(1):146-53. https://doi.org/10.1016/j.ygyno.2021.11.009
• Rafiei Sorouri Z, Kabodmehri R, Milani F, Parvari P. Red cell distribution width and mean platelet volume detection in patients with endometrial cancer and endometrial hyperplasia. Health Sci Rep. 2024;7(10):e70109. https://doi.org/10.1002/hsr2.70109
• Yayla Abide C, Bostanci Ergen E, Cogendez E, et al. Evaluation of complete blood count parameters to predict endometrial cancer. J Clin Lab Anal. 2018;32(6):e22438. https://doi.org/10.1002/jcla.22438
• Karateke A, Kaplanoglu M, Baloglu A. Relations of Platelet Indices with Endometrial Hyperplasia and Endometrial Cancer. Asian Pac J Cancer Prev. 2015;16(12):4905-8. https://doi.org/10.7314/apjcp.2015.16.12.4905
• Travaglino A, Raffone A, Saccone G, et al. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review. Acta Obstet Gynecol Scand. 2019;98(9):1086-99. https://doi.org/10.1111/aogs.13587
• Naqvi A, MacKintosh ML, Derbyshire AE, et al. The impact of obesity and bariatric surgery on the immune microenvironment of the endometrium. Int J Obes (Lond). 2022;46(3):605-12. https://doi.org/10.1038/s41366-021-01027-6